EUVIMEDOpdag EUVIMED
Crossref

A Retrospective Study to Evaluate Real-world Evidence of Azelnidipine in Indian Patients (REDEFINE Study)

Chetan Shah, Mangesh Tiwaskar, Ketan Pakhale, Amit Sinkar, Santosh Kumar Sahoo, Sarvanan Thangavelu, Mayur Jadhav, Sachin Suryawanshi, Hanmant Barkate, Sumit Bhushan, Tanmay Rane, Prashant Mishra

Journal of the Association of Physicians of India · 2024

DOI: 10.59556/japi.71.0433 ↗

At a glance

Journal article in Journal of the Association of Physicians of India, 2024. Written by Chetan Shah and 11 co-authors. Institution: Consultant Cardiologist, Heart Rhythm Clinic, Mumbai, India. Major MEDLINE topics: Dihydropyridines, Azetidinecarboxylic Acid, Hypertension, Calcium Channel Blockers. Cited 1 times so far (Crossref); 21 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

INTRODUCTION: Azelnidipine, a selective calcium channel blocker, effectively lowers blood pressure (BP) and heart rate (HR) in hypertensive patients, as demonstrated in a retrospective real-world evidence (RWE) study in Indian patients. MATERIALS AND METHODS: This was a retrospective cohort study that included 882 patients aged 18 years or older who had been on azelnidipine treatment for the last 3 months for mild to moderate hypertension (HTN). A structured proforma was utilized to gather data from prescribing physicians to assess the efficacy of azelnidipine (8 and 16 mg) as monotherapy or in combination with other antihypertensive drugs. The primary endpoints of the study were to capture changes in systolic blood pressure (SBP) and diastolic BP (DBP) from baseline to the subsequent visits (4 and 12 weeks), while the secondary endpoints were to measure similar changes in the diabetic group and to estimate the proportion of patients achieving target BP of

Subjects

MeSH terms (MEDLINE)

DihydropyridinesAzetidinecarboxylic AcidHypertensionCalcium Channel BlockersAntihypertensive AgentsBlood PressureHumansRetrospective StudiesMaleFemaleMiddle AgedIndiaAdultAgedTreatment Outcome

Substances

DihydropyridinesazelnidipineAzetidinecarboxylic AcidCalcium Channel BlockersAntihypertensive Agents

Authors and institutions

  • Consultant Cardiologist, Heart Rhythm Clinic, Mumbai, India.
  • Consultant Physician and Diabetologist, Shilpa Medical Research Center, Mumbai, India.
  • Founder and Director, Metabol - Lifestyle Metabolic Syndrome Clinic, Mumbai, India.
  • Consultant Cardiologist, Sinkar Cardiac Care, Pune, Maharashtra, India.
  • Consultant Physician, CGHS Bhubaneshwar, Bhubaneswar, Odisha, India.
  • Diabetologist and Physician, Shanmuga Diabetic Center, Coimbatore, Tamil Nadu, India.

Cite

APA

Shah, C., Tiwaskar, M., Pakhale, K., Sinkar, A., Sahoo, S. K., Thangavelu, S., Jadhav, M., Suryawanshi, S., Barkate, H., Bhushan, S., Rane, T., & Mishra, P. (2024). A Retrospective Study to Evaluate Real-world Evidence of Azelnidipine in Indian Patients (REDEFINE Study). Journal of the Association of Physicians of India. https://doi.org/10.59556/japi.71.0433

Vancouver

Shah C, Tiwaskar M, Pakhale K, Sinkar A, Sahoo SK, Thangavelu S, et al. A Retrospective Study to Evaluate Real-world Evidence of Azelnidipine in Indian Patients (REDEFINE Study). Journal of the Association of Physicians of India. 2024. doi:10.59556/japi.71.0433

BibTeX
@article{Shah2024,
  author = {Shah, Chetan and Tiwaskar, Mangesh and Pakhale, Ketan and Sinkar, Amit and Sahoo, Santosh Kumar and Thangavelu, Sarvanan and Jadhav, Mayur and Suryawanshi, Sachin and Barkate, Hanmant and Bhushan, Sumit and Rane, Tanmay and Mishra, Prashant},
  title = {A Retrospective Study to Evaluate Real-world Evidence of Azelnidipine in Indian Patients (REDEFINE Study)},
  journal = {Journal of the Association of Physicians of India},
  year = {2024},
  doi = {10.59556/japi.71.0433}
}
Start for free →